Human sC5b-9(Soluble Terminal Complement Complex C5b-9) ELISA Kit (E-EL-H2376)
Add to cart
For research use only.
Product Summary
| Sensitivity | 18.75 ng/mL |
| Detection Range | 31.25-2000 ng/mL |
| Sample Volume | 100 μL |
| Total Assay Time | 3 h 30 min |
| Reactivity | Human |
| Specificity | This kit recognizes Human sC5b-9 in samples. No significant cross-reactivity or interference between Human sC5b-9 and analogues was observed |
| Recovery | 80%-120% |
| Sample Type | Serum, plasma and other biological fluids |
| Detection Method | Colorimetric method, ELISA, Sandwich |
| Assay Type | Sandwich-ELISA |
| Size | 96T / 48T / 24T / 96T*5 / 96T*10 |
| Storage | 2-8℃ |
| Expiration Date | 12 months |
Performance
| Typical data |
The following data was generated by the Quality Control Department, under controlled laboratory conditions (ambient temperature: 18-25 °C, relative humidity: 35-75%) using standardized procedures (TMB reaction at 37 °C in the dark for 15 minutes, followed by termination and OD measurement). These values are provided for reference only.
Actual results may vary due to differences in laboratory conditions, operator technique, and equipment. Users are required to generate a standard curve using their own experimental data.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Precision |
Intra-assay Precision (Within-run Precision): Three samples representing low, mid, and high concentrations of Human IL-6 were tested 20 times on a single plate.
Inter-assay Precision (Between-run Precision): Three samples representing low, mid, and high concentrations of Human IL-6 were tested on three separate plates, with 20 replicates per plate, to assess variability among assays.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Recovery |
The recovery of Human sC5b-9 was evaluated by spiking samples at low, mid, and high concentrations across the assay range in various sample matrices.
The assay performance was assessed by comparing the measured concentrations to the expected spiked amounts to determine the percent recovery.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Linearity |
Linearity of the assay was evaluated by spiking samples with high concentrations of Human sC5b-9 and performing serial dilutions using Standard & Sample Diluent to produce concentrations spanning the assay's dynamic range.
The measured values were then compared to the expected concentrations to assess the linearity of response.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Stability |
Each kit batch is subjected to accelerated stability testing and real-time stability monitoring. Sample performance is evaluated after storage at 37 °C for 10 days to assess the impact of elevated temperature on assay reliability and reagent integrity.
|
|||||||||||||||||||||||||||||||||||||||||||||
Test Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human sC5b-9. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human sC5b-9 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human sC5b-9, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human sC5b-9. You can calculate the concentration of Human sC5b-9 in the samples by comparing the OD of the samples to the standard curve.
Background
sC5b-9 (soluble C5b-9) is a terminal complement complex that is formed as a result of activation of the complement system by classical, lectin, or alternative pathways. Therefore, measuring the sC5b-9 complex can serve as an alternative marker for terminal complement activation.
In the current study, we examined the possibility of soluble C5b-9 (sC5b9), the terminal complement complex, as a potential biomarker for TMA development in patients with active GVHD.
Traumatic brain injury (TBI) following activation of the terminal complement pathway leads to the formation of the membrane attack complex (MAC无C5b-9), which induces neuronal cell death and host-mediated secondary brain injury. Serum levels of soluble MAC (sC5b-9) have not been determined in isolated TBI patients.
Therefore, sC5b-9 as a biomarker in atypical hemolytic uria syndrome (aHUS), due to abnormal activation of the complement pathway at the cell surface level, can be detected by ELISA using plasma samples for sC5b-9, or as a stable MAC pore.
| Research Area | Immunology |
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
No files available. Please enter the correct identification code in the search area to query the relevant documents.
| Title | Status | Valid until | Action | |
|---|---|---|---|---|
| {{v.文件名}} | {{v.status_str}} | {{v.timestamp_str}} | Download | / |
*Note：Please download the relevant files within the validity period. After expiration, file preview and download will not be available on the page.
Contact with Us
Toll-free: 1-888-852-8623
Tel: 1-832-243-6086
Add:
14780 Memorial Drive, Suite 105,
Houston, Texas, 77079, USA
Houston, Texas, 77079, USA
